Image Analysis Group (IAG), a leader in clinical trial imaging and AI-powered biomarkers, has announced an expansion into the United States with a new office in Cambridge, Massachusetts. This new location in the Boston area positions IAG to enhance its collaborations with biotechnology and pharmaceutical firms, offering localized support for clinical trials within the region.
The Cambridge office is set to focus on a variety of therapeutic fields, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic, and metabolic diseases. By establishing a presence here, IAG aims to work more closely with sponsors and contract research organizations engaged in Phase I–III clinical trials and programs that require intensive imaging. The company also plans to create local job opportunities, with hires anticipated in clinical imaging operations, data science, regulatory support, and business development over the next one to two years.
IAG’s new office will bolster the company’s comprehensive imaging services, which encompass clinical trial design consultation, imaging protocol refinement, centralized image analysis, and the delivery of data that complies with regulatory standards. The company believes that its foothold in the Boston life sciences ecosystem will facilitate improved collaboration with biotech companies, pharmaceutical entities, academic institutions, and clinical research centers.
With operations spanning North America, Europe, and the Asia-Pacific region, IAG partners with pharmaceutical, biotechnology, and medical technology companies, as well as contract research organizations, to support multi-center studies. Its global framework ensures the implementation of standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for international trials.
Founded in 2007 and headquartered in London, Image Analysis Group (IAG) functions as an imaging Clinical Research Organization (iCRO). The company aids pharmaceutical, biotechnology, and medical technology firms with imaging-based clinical trial endpoints. IAG is active in areas such as oncology, inflammatory, musculoskeletal, cardiometabolic, and rare diseases. Its DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.